International Forum of Allergy & Rhinology最新文献

{"title":"Reply to “To the editor: Ambient particulate matter and frequency of outpatient visits for chronic rhinosinusitis in the United States”","authors":"Hong-Ho Yang BS, David Grimm MD, Esther Velasquez PhD, Peter H. Hwang MD","doi":"10.1002/alr.23490","DOIUrl":"10.1002/alr.23490","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"15 1","pages":"102-103"},"PeriodicalIF":7.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social factors associated with aspirin desensitization and diagnosis age in aspirin-exacerbated respiratory disease","authors":"Shravan Asthana BS,&nbsp;Alan D. Workman MD, MTR,&nbsp;David K. Lerner MD,&nbsp;Rani M. Randell BHA,&nbsp;Dana F. Lopez BS,&nbsp;Michael A. Kohanski MD, PhD,&nbsp;James N. Palmer MD,&nbsp;Nithin D. Adappa MD,&nbsp;Jennifer E. Douglas MD,&nbsp;John V. Bosso MD","doi":"10.1002/alr.23485","DOIUrl":"10.1002/alr.23485","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key points</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Racial disparities influence the completion of aspirin (ASA) desensitization and ASA-exacerbated respiratory disease (AERD) diagnosis age.</li>\u0000 \u0000 <li>Public insurance correlates with an official AERD diagnosis after age 50.</li>\u0000 \u0000 <li>Social factors, including race and insurance status, impact AERD diagnosis and adherence to ASA desensitization.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"15 1","pages":"89-92"},"PeriodicalIF":7.2,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis: A systematic review and meta-analysis”","authors":"Jenny B. Xiao,&nbsp;Helen Hsiao,&nbsp;Carlos Khalil,&nbsp;John M. Lee","doi":"10.1002/alr.23493","DOIUrl":"10.1002/alr.23493","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"15 1","pages":"101"},"PeriodicalIF":7.2,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi-institutional study.","authors":"Anthony Tang, Suchet Taori, Nicholas Fung, Joao Paulo Almeida, Pierre-Olivier Champagne, Juan C Fernandez-Miranda, Paul Gardner, Peter H Hwang, Jayakar V Nayak, Chirag Patel, Zara M Patel, Maria Peris Celda, Carlos Pinheiro-Neto, Olabisi Sanusi, Carl Snyderman, Brian D Thorp, Jamie J Van Gompel, Georgios A Zenonos, Nathan T Zwagerman, Eric W Wang, Mathew Geltzeiler, Garret Choby","doi":"10.1002/alr.23489","DOIUrl":"https://doi.org/10.1002/alr.23489","url":null,"abstract":"<p><strong>Objective: </strong>Neck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.</p><p><strong>Data sources: </strong>Retrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.</p><p><strong>Review methods: </strong>Clinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow-up time, and survival.</p><p><strong>Results: </strong>Of 258 ONB patients, 189 patients met the inclusion criteria. The 10-year neck recurrence-free survival (neck-RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time-to-event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2-80.4, p = 0.04) for neck-RFS and 9.5 for RFS at any site (95% CI 1.1-83.3, p = 0.04).</p><p><strong>Conclusion: </strong>In multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aging and frailty are associated with inflammatory endotypic shifts in patients with chronic rhinosinusitis.","authors":"Mason R Krysinski, Christina Dorismond, Yash Trivedi, Rory Lubner, Andrea A Lopez, Kolin Rubel, Rakesh K Chandra, Naweed I Chowdhury, Justin H Turner","doi":"10.1002/alr.23484","DOIUrl":"https://doi.org/10.1002/alr.23484","url":null,"abstract":"<p><strong>Key points: </strong>Frailty and aging are associated with a shift toward non-type 2 inflammation in chronic rhinosinusitis (CRS). Frailty-related shifts in sinonasal inflammatory mediators may be linked to biological senescence. Understanding the role of aging and frailty in CRS may have important treatment implications.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hops bitter β-acids have antibacterial effects against sinonasal Staphylococcus aureus but also induce sinonasal cilia and mitochondrial dysfunction.","authors":"Yobouet Ines Kouakou, Joel C Thompson, Li Hui Tan, Zoey A Miller, Ray Z Ma, Nithin D Adappa, James N Palmer, Noam A Cohen, Robert J Lee","doi":"10.1002/alr.23487","DOIUrl":"https://doi.org/10.1002/alr.23487","url":null,"abstract":"<p><strong>Background: </strong>Routine prescription of antibiotics to treat chronic rhinosinusitis (CRS) exacerbations may contribute to the propagation of antibiotic resistance. Hops bitter β-acids lupulone and colupulone possess potent antibacterial activities and, as T2R1, T2R14, and/or T2R40 agonists, may improve the impaired mucociliary clearance described in CRS patients. We investigated these molecules as alternative treatments to antibiotics in CRS management based on their antibacterial and T2Rs agonists properties.</p><p><strong>Methods: </strong>Human nasal primary cells (HNECs) and RPMI2650 cells cultures were used as study models. T2Rs expression in cell culture models and human nasal tissue was assessed using immunofluorescence, quantitative PCR, and Western blot. We performed calcium imaging and cilia beat frequency experiments to investigate T2Rs activation in study models in response to lupulone and colupulone stimulations. Finally, we studied hops β-acids cytotoxicity on cells using CellEvent, crystal violet, lactate dehydrogenase assays, immunofluorescence, and transepithelial electrical resistance assays.</p><p><strong>Results: </strong>We confirmed lupulone and colupulone potent antibacterial effect on CRS-relevant methicillin-resistant Staphylococcus aureus but found minimal impact on P. aeruginosa. We also report T2R1, T2R14 and T2R40 expression in HNECs and RPMI2650 cell cultures. Lupulone and colupulone induced an increase in cytosolic calcium that appeared dependent on T2Rs signaling. This response was accompanied by mitochondrial membrane depolarization, cellular energy stress, decreased cell proliferation, ciliostasis, and HNECs remodeling after a single exposure to lupulone at micromolar concentrations.</p><p><strong>Conclusion: </strong>Our data suggest that hops β-acids may not be beneficial as treatments in CRS patients and instead contribute to the disease by impairing cell health and further deteriorating the MCC.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps.","authors":"Christina Dorismond, Mason R Krysinski, Yash Trivedi, Rory J Lubner, Rakesh K Chandra, Naweed I Chowdhury, Justin H Turner","doi":"10.1002/alr.23483","DOIUrl":"https://doi.org/10.1002/alr.23483","url":null,"abstract":"<p><strong>Background: </strong>Despite increasing dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP), little is known about the factors influencing its use in real-world practice. We aimed to identify factors that may predict dupilumab prescription in CRSwNP patients who have undergone endoscopic sinus surgery (ESS).</p><p><strong>Methods: </strong>A single-institution, retrospective cohort study of patients who underwent ESS for CRSwNP between 2015 and 2023 was conducted. Demographics, comorbidities, 22-item sinonasal outcome test (SNOT-22) scores, and dupilumab prescription date were extracted from patient records. Intraoperative nasal mucus cytokine levels were measured using a multiplex bead assay. Univariate logistic regression analysis was performed to identify factors associated with dupilumab prescription, and multivariate logistic regression was used to adjust for surgery date.</p><p><strong>Results: </strong>A total of 299 CRSwNP patients were included, including seventy (23.4%) who were prescribed dupilumab postoperatively. Patients were more likely to be prescribed dupilumab if they had asthma (odds ratio [OR] 2.304), aspirin-exacerbated respiratory disease (AERD, OR 3.375), elevated tissue eosinophils (OR 1.005), and higher 3-month postoperative SNOT-22 scores (OR 1.027). Patients prescribed dupilumab also had greater odds of having elevated mucus interleukin (IL)-5 (OR 1.128) and IL-13 (OR 1.213). When adjusting for surgery date, associated factors included: asthma (OR 2.444), AERD (OR 3.750), allergic rhinitis (OR 1.833), higher tissue eosinophils (OR 1.005), elevated 3-month SNOT-22 scores (OR 1.028), and higher IL-5 (OR 1.123) and IL-13 (OR 1.202) levels.</p><p><strong>Conclusion: </strong>Asthma, AERD, allergic rhinitis, and elevated tissue eosinophil, IL-5, and IL-13 levels are predictive of dupilumab prescription in CRSwNP patients. These may serve as clinical and inflammatory biomarkers and can aid in counseling patients about expected disease trajectory.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of mucosal barrier disruption due to Staphylococcus lugdunensis and Staphylococcus epidermidis exoproteins in patients with chronic rhinosinusitis.","authors":"Mahnaz Ramezanpour, Sholeh Feizi, Hashan Dilendra Paththini Arachchige, George Bouras, Clare Cooksley, Gohar Shaghayegh, Peter-John Wormald, Alkis James Psaltis, Sarah Vreugde","doi":"10.1002/alr.23481","DOIUrl":"https://doi.org/10.1002/alr.23481","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis (CRS) is a persistent inflammatory condition of the sinus mucosa. While Staphylococcus aureus has been shown to play a significant role in mucosal barrier disruption in CRS patients, coagulase-negative staphylococci (CoNS) such as Staphylococcus epidermidis and Staphylococcus lugdunensis are also implicated in CRS pathophysiology. This study investigates the effects of exoproteins secreted by planktonic and biofilm forms of clinical isolates of S. epidermidis and S. lugdunensis on the nasal epithelial barrier.</p><p><strong>Methods: </strong>Thirty-one clinical isolates of CoNS were grown in planktonic and biofilm forms, and their exoproteins were concentrated. The epithelial barrier structure was assessed by measuring transepithelial electrical resistance (TEER) and the permeability of fluorescein isothiocyanate-dextran. Toxicity and inflammatory response were also studied.</p><p><strong>Results: </strong>Our findings demonstrate that exoproteins from all planktonic forms of S. lugdunensis disrupted the mucosal barrier, whereas only nine of 16 biofilm-derived exoproteins had similar effects. Conversely, 11 of 15 exoproteins from planktonic S. epidermidis significantly disrupted barrier integrity; however, biofilm exoproteins did not. The study also showed that some exoproteins from planktonic S. epidermidis significantly reduced cell viability, while exoproteins from planktonic and biofilm forms of S. lugdunensis and biofilm S. epidermidis did not induce any statistically significant change in cell viability. Notably, four of 16 biofilm exoproteins from S. lugdunensis induced higher interleukin-6 (IL-6) secretion, whereas none of the S. epidermidis isolates showed a significant increase in IL-6 secretion.</p><p><strong>Conclusion: </strong>Our results suggest that CoNS exoproteins may contribute to CRS etiopathogenesis.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidance for the evaluation by payors of claims submitted using Current Procedural Terminology codes 95165, 95115, and 95117","authors":"J. Allen Meadows MD,&nbsp;Gary N. Gross MD,&nbsp;Anita N. Wasan MD,&nbsp;Dole P. Baker MD,&nbsp;Amber Patterson MD,&nbsp;Robert Puchalski MD,&nbsp;Anil Nanda MD,&nbsp;Jami Lucas BS,&nbsp;J. Wesley Sublett MD, MPH,&nbsp;Paul V. Williams MD","doi":"10.1002/alr.23480","DOIUrl":"10.1002/alr.23480","url":null,"abstract":"<p>This Guidance was jointly developed equally by the American Academy of Allergy Asthma and Immunology (AAAAI), the American Academy of Otolaryngic Allergy (AAOA), and the American College of Allergy, Asthma and Immunology (ACAAI) to advise insurance companies and other payors of the documentation that they should, and should not, require in their review of claims for payment for services covered by Current Procedural Terminology (CPT) codes 95165, 95115, and 95117. The goal of the Guidance is to assist payors to develop a process for reviewing claims submitted under these 3 codes in a manner that is efficient, fair, and not unduly burdensome. This document supersedes any document or manual published previously by the above organizations.</p><p>The Guidance is divided into 2 parts. The first part explains each of the 3 codes, the services that are covered by these codes, and the medical necessity of those services. The second part describes what the 3 organizations believe are reasonable requests for documentation and what we submit are unreasonable requests. It first addresses code 95165 and then codes 95115 and 95117.</p><p>The AAAAI, AAOA, and ACAAI recognize that it is reasonable for insurance companies and other payors to request documentation to show that a claim submitted under CPT code 95165, 95115, or 95117 is for a medically necessary service that has been performed and has been properly coded. Accordingly, in this Guidance, we have presented the documentation that in our judgment is reasonable for payors to request. This documentation is itself quite substantial.</p><p>At the same time, we respectfully submit that demands for several kinds of additional documentation that have been made by some insurers are unnecessary. These demands serve only to make the claims process less efficient and to impose an undue burden on the entity submitting the claim—at least when the payor has no sound reason to believe that a particular claimant has acted improperly. Whenever we have characterized a particular category of requested documentation as excessive, we have sought to explain the reasons for our position.</p><p>All 3 organizations would be pleased to meet with any payor that would like to discuss this Guidance. As noted at the outset, our goal is to work with payors to assist them in developing a process for review of claims under codes 95165, 95115, and 95117 that is efficient, fair, and not unduly burdensome.</p><p>The authors declare no conflicts of interest.</p><p>The authors have no funding sources to report.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"15 1","pages":"5-8"},"PeriodicalIF":7.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alr.23480","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery versus biologics for nasal polyposis: Perspective on contemporary data","authors":"Michael J. Ye MD,&nbsp;Rodney J. Schlosser MD,&nbsp;Zachary M. Soler MD, MS,&nbsp;Jonathan B. Overdevest MD, PhD,&nbsp;David A. Gudis MD","doi":"10.1002/alr.23486","DOIUrl":"10.1002/alr.23486","url":null,"abstract":"","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"14 12","pages":"1845-1848"},"PeriodicalIF":7.2,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}